Ulysses Pharma gets patent for new antibiotic class

SHERBROOKE, Quebec Canadian drug maker Ulysses Pharma has been granted a patent for a new class of antibiotics, the company announced Tuesday.

U.S. Patent 7,410,974 covers Ulysses’ novel FQN class of antibiotics, which target drug-resistant bacteria and are designed to inhibit the development of resistance.

“The first patent secures the intellectual property on our approach to treat resistant bacteria, using new chemistry against an established antibacterial target,” said Roger Leger, Ulysses’ vice president of research and development chemistry.